Business Context and Reporting Period
This Form 8-K Current Report was filed by Aligos Therapeutics, Inc. (Nasdaq: ALGS) on January 30, 2025. The report discloses a material change in the Company's executive leadership structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel appointments rather than financial performance.
Material Changes
On January 30, 2025, the Board of Directors appointed Lesley Ann Calhoun as the Company's Chief Operating Officer (COO), effective immediately. Ms. Calhoun retains her existing title and responsibilities as Chief Financial Officer (CFO). She has served as Executive Vice President and CFO since June 2020.
Management Commentary and Risks
The filing details Ms. Calhoun's extensive background in the biopharmaceutical sector, including prior roles at Global Blood Therapeutics, Hyperion Therapeutics, and Innoviva, Inc., as well as her experience as a Director and Audit Committee Chair at Tango Therapeutics, Inc. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Confirm the effective date of the COO appointment (January 30, 2025).
- Verify that Ms. Calhoun continues to serve as CFO alongside her new COO role.
- Review Ms. Calhoun's prior experience at Global Blood Therapeutics and Tango Therapeutics for relevant industry expertise.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.